Products Fingolimod
Fingolimod Pre-clinical Completed 💤 Quiet Interest: 26/100
Oct 15, 2011 → May 29, 2024
About Fingolimod Fingolimod is a pre-clinical stage product being developed by Novartis for Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01285479. Target conditions include Multiple Sclerosis.
What happened to similar drugs? 20 of 20 similar drugs in Multiple Sclerosis were approved
Clinical Trials (16) NCT ID Phase Status Start Completion Indication NCT04480853 Approved Recruiting Oct 12, 2020 Sep 30, 2027 Multiple Sclerosis NCT05141669 Pre-clinical Completed May 18, 2020 Nov 20, 2020 Multiple Sclerosis NCT03257358 Approved Completed Sep 19, 2017 Jun 28, 2019 Relapsing Multiple Sclerosis NCT02720107 Approved Completed May 12, 2016 Nov 14, 2016 Relapsing-remitting Multiple Sclerosis NCT02232061 Approved Completed Sep 29, 2014 Jan 24, 2020 Multiple Sclerosis NCT01621269 Approved Withdrawn Jun 1, 2013 Jun 1, 2014 Multiple Sclerosis NCT01755871 Approved Terminated Jan 1, 2013 Feb 1, 2016 Relapsing Remitting Multiple Sclerosis NCT01578330 Approved Completed Oct 1, 2012 Apr 1, 2015 Multiple Sclerosis NCT01705236 Approved Completed Aug 20, 2012 Feb 18, 2019 Relapsing Remitting Multiple Sclerosis RRMS NCT01497262 Phase 3 Completed Feb 1, 2012 Apr 1, 2014 Multiple Sclerosis NCT01285479 Pre-clinical Completed Oct 15, 2011 May 29, 2024 Multiple Sclerosis NCT01420055 Approved Completed Aug 1, 2011 Jun 1, 2013 Multiple Sclerosis, Relapsing-Remitting NCT01281657 Pre-clinical Completed Feb 1, 2011 Jul 1, 2012 Multiple Sclerosis NCT01310166 Approved Completed Feb 1, 2011 Jul 1, 2012 Relapsing-remitting Multiple Sclerosis NCT01201356 Phase 3 Completed Sep 13, 2010 Oct 19, 2018 Relapsing Forms of Multiple Sclerosis NCT00670449 Phase 2 Completed Apr 1, 2008 Apr 1, 2012 Multiple Sclerosis
Product Company Stage Hype Score mRNA-1195 Moderna Phase 2 NEX-20A Nanexa AB Phase 1 mRNA-2736 Moderna Phase 1 mRNA-2808 Moderna Phase 2 Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2